Interpharm Operating Cycle from 2010 to 2026

IPAH Stock  USD 0  0.00  0.00%   
Interpharm Holdings' Operating Cycle is increasing with slightly volatile movements from year to year. Operating Cycle is estimated to finish at 169.71 this year. For the period between 2010 and 2026, Interpharm Holdings, Operating Cycle quarterly trend regression had mean deviation of  14.55 and range of 122. View All Fundamentals
 
Operating Cycle  
First Reported
2010-12-31
Previous Quarter
161.63
Current Value
169.71
Quarterly Volatility
29.6461781
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Interpharm Holdings financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Interpharm Holdings' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 9.1 M or Total Revenue of 56.6 M, as well as many indicators such as Price To Sales Ratio of 0.0105, Dividend Yield of 0.16 or PTB Ratio of 0.0696. Interpharm financial statements analysis is a perfect complement when working with Interpharm Holdings Valuation or Volatility modules.
  
Build AI portfolio with Interpharm Stock
Check out the analysis of Interpharm Holdings Correlation against competitors.
For more detail on how to invest in Interpharm Stock please use our How to Invest in Interpharm Holdings guide.

Latest Interpharm Holdings' Operating Cycle Growth Pattern

Below is the plot of the Operating Cycle of Interpharm Holdings over the last few years. It is Interpharm Holdings' Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Interpharm Holdings' overall financial position and show how it may be relating to other accounts over time.
Operating Cycle10 Years Trend
Slightly volatile
   Operating Cycle   
       Timeline  

Interpharm Operating Cycle Regression Statistics

Arithmetic Mean170.75
Geometric Mean166.31
Coefficient Of Variation17.36
Mean Deviation14.55
Median179.58
Standard Deviation29.65
Sample Variance878.90
Range122
R-Value0.32
Mean Square Error839.57
R-Squared0.10
Significance0.21
Slope1.90
Total Sum of Squares14,062

Interpharm Operating Cycle History

2026 169.71
2025 161.63
2011 179.58
2010 57.24

About Interpharm Holdings Financial Statements

Investors use fundamental indicators, such as Interpharm Holdings' Operating Cycle, to determine how well the company is positioned to perform in the future. Although Interpharm Holdings' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Operating Cycle 161.63  169.71 

Currently Active Assets on Macroaxis

When determining whether Interpharm Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Interpharm Holdings' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Interpharm Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Interpharm Holdings Stock:
Check out the analysis of Interpharm Holdings Correlation against competitors.
For more detail on how to invest in Interpharm Stock please use our How to Invest in Interpharm Holdings guide.
You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Interpharm Holdings. If investors know Interpharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Interpharm Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.09)
Revenue Per Share
1.048
Quarterly Revenue Growth
(0.07)
Return On Assets
(0.19)
Return On Equity
(1.17)
The market value of Interpharm Holdings is measured differently than its book value, which is the value of Interpharm that is recorded on the company's balance sheet. Investors also form their own opinion of Interpharm Holdings' value that differs from its market value or its book value, called intrinsic value, which is Interpharm Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Interpharm Holdings' market value can be influenced by many factors that don't directly affect Interpharm Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Interpharm Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Interpharm Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Interpharm Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.